$XBP
XBP Europe Holdings Inc Stock $xbp

$xbp Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000121390023086215 Filed on November 13, 2023

Income Statement

Concept	2023 Q3
Revenue	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit	$9.255M
YoY Change
Gross Profit Margin
Selling, General & Admin	$820.0K
YoY Change	-31.03%
% of Gross Profit	8.86%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$745.0K
YoY Change
% of Gross Profit	8.05%
Operating Expenses	$820.0K
YoY Change	-31.03%
Operating Profit	-$823.4K
YoY Change	-30.74%
Interest Expense	$210.0K
YoY Change	237.89%
% of Operating Profit
Other Income/Expense, Net	-$1.490M
YoY Change	-460.15%
Pretax Income	-$19.00M
YoY Change	2564.65%
Income Tax	$41.40K
% Of Pretax Income
Net Earnings	-$19.04M
YoY Change	2247.12%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.13
Diluted Earnings Per Share	-$2.35
COMMON SHARES
Basic Shares Outstanding	21.80M
Diluted Shares Outstanding	21.80M

Balance Sheet

Concept	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$100.0K
YoY Change	-62.29%
Cash & Equivalents	$65.00K
Short-Term Investments
Other Short-Term Assets	$0.00
YoY Change	-100.0%
Inventory
Prepaid Expenses	$17.50K
Receivables
Other Receivables
Total Short-Term Assets	$82.50K
YoY Change	-70.54%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$7.800M
YoY Change	-74.99%
Other Assets
YoY Change
Total Long-Term Assets	$7.835M
YoY Change	-74.88%
TOTAL ASSETS
Total Short-Term Assets	$82.50K
Total Long-Term Assets	$7.835M
Total Assets	$7.918M
YoY Change	-74.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses	$1.703M
YoY Change	106.65%
Deferred Revenue
YoY Change
Short-Term Debt	$9.900M
YoY Change	21.46%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$11.65M
YoY Change	27.94%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00
YoY Change
Other Long-Term Liabilities	$21.60M
YoY Change	826.02%
Total Long-Term Liabilities	$21.60M
YoY Change	826.02%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.65M
Total Long-Term Liabilities	$21.60M
Total Liabilities	$33.30M
YoY Change	191.1%
SHAREHOLDERS EQUITY
Retained Earnings	-$33.34M
YoY Change	199.3%
Common Stock	$554.00
YoY Change	925.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$33.01M
YoY Change
Total Liabilities & Shareholders Equity	$7.918M
YoY Change	-74.84%

Cashflow Statement

Concept	2023 Q3
OPERATING ACTIVITIES
Net Income	-$19.04M
YoY Change	2247.12%
Depreciation, Depletion And Amortization	$745.0K
YoY Change
Cash From Operating Activities	$0.00
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$8.040M
YoY Change	-95.89%
Cash From Investing Activities	$8.040M
YoY Change	-95.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-8.000M
YoY Change	-95.93%
NET CHANGE
Cash From Operating Activities	0.000
Cash From Investing Activities	8.040M
Cash From Financing Activities	-8.000M
Net Change In Cash	40.00K
YoY Change	-103.31%
FREE CASH FLOW
Cash From Operating Activities	$0.00
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent		usd
	us-gaap	Other Income OtherIncome		usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q3	us-gaap	Other Income OtherIncome		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Registrant Name EntityRegistrantName	CF ACQUISITION CORP. VIII
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity File Number EntityFileNumber	001-40206
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-2002883
	dei	Entity Address Address Line1 EntityAddressAddressLine1	110 East 59th Street
	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10022
	dei	City Area Code CityAreaCode	(212)
	dei	Local Phone Number LocalPhoneNumber	938-5000
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	true
CY2023Q3	us-gaap	Cash Cash	65000	usd
CY2022Q4	us-gaap	Cash Cash	41154	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	17500	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	210241	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	82500	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	251395	usd
CY2023Q3	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	7835221	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	31445874	usd
CY2023Q3	us-gaap	Assets Assets	7917721	usd
CY2022Q4	us-gaap	Assets Assets	31697269	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	40000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	70065	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	11648989	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9459903	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1702927	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1189676	usd
CY2023Q3	cffe	Notes Payables Related Parties Classified Current NotesPayablesRelatedPartiesClassifiedCurrent	9906062	usd
CY2022Q4	cffe	Notes Payables Related Parties Classified Current NotesPayablesRelatedPartiesClassifiedCurrent	8200162	usd
CY2023Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1596250	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	178780	usd
CY2023Q3	cffe	Forward Purchase Securities Liability ForwardPurchaseSecuritiesLiability	20050252	usd
CY2022Q4	cffe	Forward Purchase Securities Liability ForwardPurchaseSecuritiesLiability	2504214	usd
CY2023Q3	us-gaap	Liabilities Liabilities	33295491	usd
CY2022Q4	us-gaap	Liabilities Liabilities	12142897	usd
CY2023Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	7628136	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	31169832	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	554	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	54	usd
CY2023Q3	cffe	Common Stock Value1 CommonStockValue1	125	usd
CY2022Q4	cffe	Common Stock Value1 CommonStockValue1	625	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	328730	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	694592	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-33335315	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-12310731	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-33005906	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-11615460	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7917721	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	31697269	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	770927	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1108906	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1708519	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1913161	usd
CY2023Q3	cffe	Related Party Transaction Selling General And Administrative Expenses From Transaction With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionWithRelatedParty	30000	usd
CY2022Q3	cffe	Related Party Transaction Selling General And Administrative Expenses From Transaction With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionWithRelatedParty	30000	usd
	cffe	Related Party Transaction Selling General And Administrative Expenses From Transaction With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionWithRelatedParty	90000	usd
	cffe	Related Party Transaction Selling General And Administrative Expenses From Transaction With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionWithRelatedParty	90000	usd
CY2023Q3	us-gaap	Taxes Other TaxesOther	22483	usd
CY2022Q3	us-gaap	Taxes Other TaxesOther	50000	usd
	us-gaap	Taxes Other TaxesOther	160000	usd
	us-gaap	Taxes Other TaxesOther	112534	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-823410	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1188906	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1958519	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2115695	usd
CY2023Q3	us-gaap	Interest Income Other InterestIncomeOther	168755	usd
CY2022Q3	us-gaap	Interest Income Other InterestIncomeOther	518498	usd
	us-gaap	Interest Income Other InterestIncomeOther	753119	usd
	us-gaap	Interest Income Other InterestIncomeOther	956908	usd
CY2023Q3	cffe	Interest Expense Mandatorily Redeemable Securities InterestExpenseMandatorilyRedeemableSecurities	210484	usd
CY2022Q3	cffe	Interest Expense Mandatorily Redeemable Securities InterestExpenseMandatorilyRedeemableSecurities	689606	usd
	cffe	Interest Expense Mandatorily Redeemable Securities InterestExpenseMandatorilyRedeemableSecurities	788591	usd
	cffe	Interest Expense Mandatorily Redeemable Securities InterestExpenseMandatorilyRedeemableSecurities	689606	usd
	us-gaap	Other Income OtherIncome	579294	usd
CY2023Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1279554	usd
CY2022Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1103328	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1417470	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-4725538	usd
CY2023Q3	cffe	Change In Fair Value Of Forward Purchase Securities Liability ChangeInFairValueOfForwardPurchaseSecuritiesLiability	16858881	usd
CY2022Q3	cffe	Change In Fair Value Of Forward Purchase Securities Liability ChangeInFairValueOfForwardPurchaseSecuritiesLiability	456349	usd
	cffe	Change In Fair Value Of Forward Purchase Securities Liability ChangeInFairValueOfForwardPurchaseSecuritiesLiability	17546038	usd
	cffe	Change In Fair Value Of Forward Purchase Securities Liability ChangeInFairValueOfForwardPurchaseSecuritiesLiability	-248606	usd
CY2023Q3	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-19003574	usd
CY2022Q3	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-713035	usd
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-20957499	usd
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	3705045	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	41401	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	98385	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	67085	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	138616	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-19044975	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-811420	usd
	us-gaap	Net Income Loss NetIncomeLoss	-21024584	usd
	us-gaap	Net Income Loss NetIncomeLoss	3566429	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-11615460	usd
CY2023Q1	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	242210	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1593525	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-13451195	usd
CY2023Q2	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	154338	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-386084	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-13991617	usd
CY2023Q3	cffe	Accretion Of Redeemable Shares Of Class A Common Stock To Redemption Value AccretionOfRedeemableSharesOfClassACommonStockToRedemptionValue	30686	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-19044975	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-33005906	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-9352134	usd
CY2022Q1	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	4424015	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	49411	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	3412413	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-10314325	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	965436	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-329250	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-9678139	usd
CY2022Q3	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	976833	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-811420	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	329250	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-11137142	usd
	us-gaap	Net Income Loss NetIncomeLoss	-21024584	usd
	us-gaap	Net Income Loss NetIncomeLoss	3566429	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	49411	usd
	cffe	General And Administrative Expenses Paid By Related Party GeneralAndAdministrativeExpensesPaidByRelatedParty	834504	usd
	cffe	General And Administrative Expenses Paid By Related Party GeneralAndAdministrativeExpensesPaidByRelatedParty	1487194	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	753119	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	956908	usd
	us-gaap	Interest Expense Other InterestExpenseOther	788591	usd
	us-gaap	Interest Expense Other InterestExpenseOther	689606	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1417470	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-4725538	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	17546038	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-248606	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-707914	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-810931	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	513251	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-525068	usd
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	-30065	usd
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	-147451	usd
	us-gaap	Payments To Acquire Assets Investing Activities PaymentsToAcquireAssetsInvestingActivities	344781	usd
	us-gaap	Payments To Acquire Assets Investing Activities PaymentsToAcquireAssetsInvestingActivities	5400847	usd
	cffe	Proceeds From Trust Account To Pay Franchise Taxes ProceedsFromTrustAccountToPayFranchiseTaxes	230115	usd
	cffe	Proceeds From Trust Account To Pay Franchise Taxes ProceedsFromTrustAccountToPayFranchiseTaxes	264301	usd
	cffe	Proceeds From Trust Account To Pay Income Taxes ProceedsFromTrustAccountToPayIncomeTaxes	112000	usd
	cffe	Proceeds From Trust Account Torepayoverdraftfacility ProceedsFromTrustAccountTorepayoverdraftfacility	62406	usd
	cffe	Proceeds From Trust Account To Redeem Public Shares ProceedsFromTrustAccountToRedeemPublicShares	24304031	usd
	cffe	Proceeds From Trust Account To Redeem Public Shares ProceedsFromTrustAccountToRedeemPublicShares	224920621	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	224056750	usd
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	225000000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	224056750	usd
	cffe	Maturity Of Availableforsale Debt Securities Held In The Trust Account MaturityOfAvailableforsaleDebtSecuritiesHeldInTheTrustAccount	225000000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	24363771	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	219784075	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1376189	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	7416422	usd
	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	24366437	usd
	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	224920621	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	1349677	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	2039688	usd
	us-gaap	Proceeds From Repayments Of Bank Overdrafts ProceedsFromRepaymentsOfBankOverdrafts	62406	usd
	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	62406	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-24339925	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-219543887	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	23846	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	240188	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	41154	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	65000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	265188	usd
	cffe	Prepaid Expenses Paid With Payables To Related Party PrepaidExpensesPaidWithPayablesToRelatedParty	515173	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	112000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 1—Description of Organization, Business Operations and Basis of Presentation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.35pt">CF Acquisition Corp. VIII (the “Company”) was incorporated in Delaware on July 8, 2020. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.35pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.35pt">Although the Company is not limited in its search for target businesses to a particular industry or sector for the purpose of consummating the Business Combination, the Company intends to focus its search on companies operating in the financial services, healthcare, real estate services, technology and software industries. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.35pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2023, the Company had not commenced operations. All activity through September 30, 2023 relates to the Company’s formation, the initial public offering (the “Initial Public Offering”) described below, and the Company’s efforts toward locating and completing a suitable Business Combination. The Company will not generate any operating revenues until after the completion of the Business Combination, at the earliest. During the nine months ended September 30, 2023 and the three and nine months ended September 30, 2022, the Company generated non-operating income in the form of interest income on investments in money market funds that invested in U.S. government debt securities and classified as cash equivalents from the proceeds derived from the Initial Public Offering. In addition, during the three and nine months ended September 30, 2023, the Company generated non-operating income in the form of interest income from cash deposited in a demand account held at a U.S. bank. During the three and nine months ended September 30, 2022, the Company also generated non-operating income in the form of interest income from direct investments in U.S. government debt securities. During the three and nine months ended September 30, 2023 and 2022, the Company recognized changes in the fair value of the warrant liability and FPS (as defined below) liability as other income (loss).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s sponsor is CFAC Holdings VIII, LLC (the “Sponsor”). The registration statements for the Initial Public Offering became effective on March 11, 2021. On March 16, 2021, the Company consummated the Initial Public Offering of 25,000,000 units (each, a “Unit” and with respect to the shares of Class A common stock included in the Units sold, the “Public Shares”), including 3,000,000 Units sold upon the partial exercise of the underwriters’ over-allotment option, at a purchase price of $10.00 per Unit, generating gross proceeds of $250,000,000, which is described in Note 3. Each Unit consists of one share of Class A common stock and one-fourth of one redeemable warrant. Each whole warrant entitles the holder to purchase one share of Class A common stock at a price of $11.50. Each warrant will become exercisable 30 days after the completion of the Business Combination and will expire 5 years after the completion of the Business Combination, or earlier upon redemption or liquidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 540,000 units (the “Private Placement Units”) at a price of $10.00 per Private Placement Unit to the Sponsor in a private placement, generating gross proceeds of $5,400,000, which is described in Note 4. The proceeds of the Private Placement Units were deposited into the Trust Account (as defined below) and will be used to fund the redemption of the Public Shares subject to the requirements of applicable law (see Note 4).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Offering costs amounted to approximately $4,900,000, consisting of $4,500,000 of underwriting fees and approximately $400,000 of other costs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the closing of the Initial Public Offering and sale of the Private Placement Units on March 16, 2021, an amount of $250,000,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Units (see Note 4) was placed in a trust account (the “Trust Account”) located in the United States at J.P. Morgan Chase Bank, N.A., with Continental Stock Transfer & Trust Company (“Continental”) acting as trustee, which were initially invested only in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 185 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting the conditions of paragraphs (d)(2), (d)(3) and (d)(4) of Rule 2a-7 of the Investment Company Act, as determined by the Company. To mitigate the risk of the Company being deemed to be an unregistered investment company (including under the subjective test of Section 3(a)(1)(A) of the Investment Company Act) and thus be subject to regulation under the Investment Company Act, on March 16, 2023, the 24-month anniversary of the effective date of the registration statement for the Initial Public Offering, the Company instructed Continental, the trustee with respect to the Trust Account,</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">to liquidate the investments held in the Trust Account and instead to hold the funds in the Trust Account in an interest-bearing demand deposit account at Citibank, N.A., with Continental continuing to act as trustee, until the earlier of the consummation of the Business Combination or the distribution of the Trust Account. As a result, following the liquidation of investments in the Trust Account, the remaining proceeds from the Initial Public Offering and Private Placement are no longer invested in U.S. government debt securities or money market funds that invest in U.S. government debt securities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Merger Agreement with XBP Europe, Inc. –</b> On October 9, 2022, the Company entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the “Merger Agreement”) by and among the Company, Sierra Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of the Company (“Merger Sub”), BTC International Holdings, Inc., a Delaware corporation (“Parent”), and XBP Europe, Inc., a Delaware corporation and a direct wholly owned subsidiary of Parent (“XBP Europe”). Pursuant to the Merger Agreement, subject to the terms and conditions set forth therein, Merger Sub will merge with and into XBP Europe (the “Merger” and together with the other transactions contemplated by the Merger Agreement, the “XBP Europe Business Combination”) whereby the separate existence of Merger Sub will cease and XBP Europe will be the surviving corporation of the Merger and become a wholly owned subsidiary of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The board of directors and stockholders of the Company have approved the Merger and the XBP Europe Business Combination. The closing of the XBP Europe Business Combination is subject to customary closing conditions, including the receipt of certain regulatory approvals.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain existing agreements of the Company, including, but not limited to, the business combination marketing agreement, have been or will be amended or amended and restated in connection with the XBP Europe Business Combination, all as further described in the definitive proxy statement filed by the Company with the SEC on August 4, 2023 (the “XBP Europe Proxy Statement”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For more information related to the XBP Europe Business Combination, reference should be made to the Form 8-K that was filed by the Company with the SEC on October 11, 2022, the XBP Europe Proxy Statement and the other filings that the Company has made with the SEC.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Initial Business Combination –</b> The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward consummating the Business Combination, including the XBP Europe Business Combination. There is no assurance that the Company will be able to complete the Business Combination successfully. The Company must complete one or more Business Combinations having an aggregate fair market value of at least 80% of the assets held in the Trust Account (excluding taxes payable on income earned on the Trust Account) at the time of the agreement to enter into the initial Business Combination. However, the Company will only complete the Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company will provide the holders of the Public Shares (the “public stockholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of the Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of the Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The public stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account. The per share amount to be distributed to public stockholders who redeem the Public Shares will not be reduced by the Marketing Fee (as defined in Note 4). There will be no redemption rights upon the completion of the Business Combination with respect to the Company’s warrants. The Company will proceed with the Business Combination only if the Company has net tangible assets of at least $5,000,001 either immediately prior to or upon such consummation of the Business Combination and a majority of the shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote for business or other legal reasons, the Company will, pursuant to its amended and restated certificate of incorporation (as may be amended, the “Amended and Restated Certificate of Incorporation”), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (the “SEC”) and file tender offer documents with the SEC prior to completing the Business Combination. If, however, stockholder approval of the Business Combination is required by law, or the Company decides to obtain stockholder approval for business or legal reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each public stockholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed Business Combination. If the Company seeks stockholder approval in connection with the Business Combination, the initial stockholders (as defined below) have agreed to vote their Founder Shares (as defined in Note 4), their Private Placement Shares (as defined in Note 4) and any Public Shares purchased during or after the Initial Public Offering in favor of the Business Combination. In addition, the initial stockholders have agreed to waive their redemption rights with respect to their Founder Shares and any Public Shares held by the initial stockholders in connection with the completion of the Business Combination.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding the foregoing, the Amended and Restated Certificate of Incorporation provides that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the Class A common stock sold in the Initial Public Offering, without the prior consent of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 24, 2023, the Company held a special meeting of stockholders (the “Special Meeting”) in connection with the XBP Europe Business Combination, at which the stockholders approved the XBP Europe Business Combination. The closing of the XBP Europe Business Combination is subject to customary closing conditions, including the receipt of certain regulatory approvals.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Sponsor and the Company’s officers and directors (the “initial stockholders”) have agreed not to propose an amendment to the Amended and Restated Certificate of Incorporation (i) that would affect the substance or timing of the Company’s obligation to allow redemption in connection with the Business Combination or to redeem 100% of the Public Shares if the Company does not complete the Business Combination or (ii) with respect to any other provision relating to stockholders’ rights or pre-business combination activity, unless the Company provides the public stockholders with the opportunity to redeem their Public Shares in conjunction with any such amendment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Forward Purchase Contract</b> — In connection with the Initial Public Offering, the Sponsor committed, pursuant to a forward purchase contract with the Company (the “FPA”), to purchase, in a private placement for gross proceeds of $10,000,000 to occur concurrently with the consummation of the initial Business Combination, 1,000,000 of the Company’s Units on substantially the same terms as the sale of Units in the Initial Public Offering at $10.00 per Unit, and 250,000 shares of Class A common stock (for no additional consideration) (the securities issuable pursuant to the FPA, the “FPS”). The funds from the sale of the FPS will be used as part of the consideration to the sellers in the initial Business Combination; any excess funds from this private placement will be used for working capital in the post-transaction company. This commitment is independent of the percentage of stockholders electing to redeem their Public Shares and provides the Company with a minimum funding level for the initial Business Combination.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Failure to Consummate a Business Combination </b>— The Company has until March 16, 2024 (which was originally March 16, 2022 and has been extended by the Extensions (as defined below)), or a later date approved by the Company’s stockholders in accordance with the Amended and Restated Certificate of Incorporation, to consummate the Business Combination (the “Combination Period”). If the Company is unable to complete the Business Combination by the end of the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest earned on the funds held in the Trust Account and not previously released to the Company to pay taxes, other than excise tax (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding Public Shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and the Company’s board of directors, dissolve and liquidate, subject in the case of clauses (ii) and (iii), to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire worthless if the Company fails to complete the Business Combination within the Combination Period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 8, 2022, at a special meeting of the Company’s stockholders, the Company’s stockholders approved an extension of the expiration of the period in which the Company has to consummate the Business Combination from March 16, 2022 to September 30, 2022 (the “First Extension”). In connection with the First Extension, on March 9, 2022, the Sponsor loaned the Company an aggregate amount of $4,424,015 ($0.20 for each Public Share that was not redeemed in connection with the First Extension) (the “First Extension Loan”). The proceeds of the First Extension Loan were deposited into the Trust Account on March 9, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 27, 2022, at a special meeting of the Company’s stockholders, the Company’s stockholders approved an additional extension of the expiration of the period in which the Company has to consummate the Business Combination from September 30, 2022 to March 16, 2023 (the “Second Extension”). In connection with the Second Extension, on September 30, 2022, the Sponsor loaned the Company an aggregate amount of $976,832 ($0.33 for each Public Share that was not redeemed in connection with the Second Extension) (the “Second Extension Loan”). The proceeds of the Second Extension Loan were deposited into the Trust Account on September 30, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 14, 2023, at a special meeting of the Company’s stockholders, the Company’s stockholders approved an additional extension of the expiration of the period in which the Company has to consummate the Business Combination from March 16, 2023 to September 16, 2023 or an earlier date determined by the board of directors of the Company (the “Third Extension”). In connection with the Third Extension, the Sponsor loaned the Company an aggregate amount of $344,781 (the “Third Extension Loan”). In connection with the stockholder vote to approve the Third Extension, 1,523,509 Public Shares were redeemed at approximately $10.69 a share, resulting in a reduction of $16,290,945 in the amount held in the Trust Account.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 14, 2023, at a special meeting of the Company’s stockholders, the Company’s stockholders approved an additional extension of the expiration of the period in which the Company has to consummate the Business Combination from September 16, 2023 to March 16, 2024 or an earlier date determined by the board of directors of the Company (the “Fourth Extension,” and together with the First Extension, the Second Extension and the Third Extension, the “Extensions”). In connection with the stockholder vote to approve the Fourth Extension, 730,270 Public Shares were redeemed at approximately $11.06 a share, resulting in a reduction of $8,075,492 in the amount held in the Trust Account.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each of the First Extension Loan, the Second Extension Loan and the Third Extension Loan bears no interest and is due and payable on the date on which the Company consummates the initial Business Combination. The principal balance of each loan may be prepaid at any time with funds outside of the Trust Account.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms and conditions of the XBP Europe Business Combination, in connection with the consummation of the XBP Europe Business Combination, all amounts outstanding under each of the First Extension Loan, the Second Extension Loan and the Third Extension Loan will be converted into shares of Class A common stock at $10.00 per share in accordance with, and subject to the exceptions set forth in, the Merger Agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The XBP Europe Business Combination is anticipated to close during the Combination Period. If the XBP Europe Business Combination does not close during the Combination Period, the Company may seek approval from its stockholders to further extend the Combination Period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The initial stockholders have agreed to waive their liquidation rights from the Trust Account with respect to the Founder Shares and the Private Placement Shares if the Company fails to complete the Business Combination within the Combination Period. However, if the initial stockholders acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete the Business Combination within the Combination Period. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be less than $10.00 per share initially held in the Trust Account. In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account below $10.00 per share. This liability will not apply with respect to any claims by a third party who executed a waiver of any right, title, interest or claim of any kind in or to any monies held in the Trust Account or to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers, prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account, except for the Company’s underwriters and independent registered public accounting firm.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Liquidity and Capital Resources</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2023 and December 31, 2022, the Company had $65,000 and approximately $41,200, respectively, of cash in its operating account. As of September 30, 2023 and December 31, 2022, the Company had a working capital deficit of approximately $11,566,000 and $9,209,000, respectively. As of September 30, 2023 and December 31, 2022, approximately $228,000 and $276,000, respectively, of interest income earned on funds held in the Trust Account was available to pay taxes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s liquidity needs through September 30, 2023 have been satisfied through a contribution of $25,000 from the Sponsor in exchange for the issuance of the Founder Shares, a loan of approximately $79,000 from the Sponsor pursuant to a promissory note (the “Pre-IPO Note”) (see Note 4), the proceeds from the sale of the Private Placement Units not held in the Trust Account, the Sponsor Loan (as defined below), the First Working Capital Loan (as defined below), the Second Working Capital Loan (as defined below), the Third Working Capital Loan (as defined below) and the Fourth Working Capital Loan (as defined below). The Company fully repaid the Pre-IPO Note upon completion of the Initial Public Offering. In addition, in order to finance transaction costs in connection with the Business Combination, the Sponsor loaned the Company $1,750,000 to fund the Company’s expenses relating to investigating and selecting a target business and other working capital requirements after the Initial Public Offering and prior to the Business Combination (the “Sponsor Loan”). If the Sponsor Loan is insufficient, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, provide the Company with Working Capital Loans (as defined in Note 4).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 9, 2022, the Company borrowed $4,424,015 ($0.20 for each Public Share that was not redeemed in connection with the First Extension) from the Sponsor pursuant to the First Extension Loan, which was deposited into the Trust Account.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 30, 2022, the Company entered into a Working Capital Loan (the “First Working Capital Loan”) with the Sponsor in the amount of up to $1,000,000 in connection with advances the Sponsor has made to the Company for working capital expenses, which First Working Capital Loan has been fully drawn by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 30, 2022, the Company borrowed $976,832 ($0.33 for each Public Share that was not redeemed in connection with the Second Extension) from the Sponsor pursuant to the Second Extension Loan, which was deposited into the Trust Account.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 14, 2022, the Company entered into a second Working Capital Loan with the Sponsor in the amount of up to $750,000 (the “Second Working Capital Loan”) in connection with advances the Sponsor has made to the Company for working capital expenses, which Second Working Capital Loan has been fully drawn by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 15, 2023, the Company entered into the Third Extension Loan with the Sponsor, pursuant to which the Sponsor loaned the Company $344,781 in the aggregate. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 31, 2023, the Company entered into a third Working Capital Loan with the Sponsor in the amount of up to $500,000 (the “Third Working Capital Loan”) in connection with advances the Sponsor has made to the Company for working capital expenses, which Third Working Capital Loan has been fully drawn by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 31, 2023, the Company entered into a fourth Working Capital Loan with the Sponsor in the amount of up to $300,000 (the “Fourth Working Capital Loan”) in connection with advances the Sponsor has made and will make to the Company for working capital expenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each of the First Extension Loan, the First Working Capital Loan, the Second Extension Loan, the Second Working Capital Loan, the Third Extension Loan, the Third Working Capital Loan and the Fourth Working Capital Loan bears no interest and is due and payable on the date on which the Company consummates the initial Business Combination. The principal balance of each loan may be prepaid at any time with funds outside of the Trust Account.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms and conditions of the XBP Europe Business Combination, in connection with the consummation of the XBP Europe Business Combination, all amounts outstanding under each of the Sponsor Loan, the First Working Capital Loan, the Second Working Capital Loan, the Third Working Capital Loan, the Fourth Working Capital Loan, the First Extension Loan, the Second Extension Loan and the Third Extension Loan will be converted into shares of Class A common stock at $10.00 per share in accordance with, and subject to the exceptions set forth in, the Merger Agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2023 and December 31, 2022, the carrying amounts of the loans payable by the Company to the Sponsor were approximately $9,906,000 and $8,200,000, respectively. As of September 30, 2023 and December 31, 2022, the face amounts of these loans were approximately $9,906,000 and $8,500,000, respectively. See <i>“Related Party Loans” </i>below for additional information.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on the foregoing, management believes that the Company will have sufficient working capital and borrowing capacity from the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors, to meet its needs through the earlier of the consummation of the Business Combination or one year from this filing. Over this time period, the Company will be using these funds for paying existing accounts payable, identifying and evaluating prospective target businesses, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basis of Presentation</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited condensed consolidated financial statements are presented in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC and reflect all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the financial position as of September 30, 2023 and the results of operations and cash flows for the periods presented. Certain information and disclosures normally included in unaudited condensed consolidated financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations. Interim results are not necessarily indicative of results for a full year or any future period. The accompanying unaudited consolidated condensed financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Form 10-K and the final prospectus filed by the Company with the SEC on March 29, 2023 and March 15, 2021, respectively and our Form 10-K/A for the year ended December 31, 2022, as filed with the SEC on April 25, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Principles of Consolidation</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited condensed consolidated financial statements of the Company include its wholly-owned subsidiary. All intercompany accounts and transactions are eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Going Concern</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Company’s going concern considerations in accordance with guidance in the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) 205-40, <i>Presentation of Financial Statements – Going Concern</i>, the Company has until March 16, 2024 to consummate the Business Combination. The Company’s mandatory liquidation date, if the Business Combination is not consummated, raises substantial doubt about the Company’s ability to continue as a going concern. These unaudited condensed consolidated financial statements do not include any adjustments related to the recovery of the recorded assets or the classification of the liabilities should the Company be unable to continue as a going concern. As discussed in Note 1, in the event of a mandatory liquidation, within ten business days, the Company will redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest earned on the funds held in the Trust Account and not previously released to the Company to pay taxes, other than excise tax (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding Public Shares.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Emerging Growth Company</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is an “emerging growth company”, as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This may make comparison of the Company’s unaudited condensed consolidated financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Inflation Reduction Act of 2022 </i></b></p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 16, 2022, the Inflation Reduction Act of 2022 (the “IR Act”) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise tax on certain repurchases (including redemptions) of stock by publicly traded U.S. corporations and certain U.S. subsidiaries of publicly traded foreign corporations that occur after December 31, 2022. The excise tax is imposed on the repurchasing corporation itself and not its stockholders from which the shares are repurchased. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the “Treasury Department”) has authority to promulgate regulations and provide other guidance regarding the excise tax. In December 2022, the Treasury Department issued Notice 2023-2, <i>Initial Guidance Regarding the Application of the Excise Tax on Repurchases of Corporate Stock under Section 4501 of the Internal Revenue Code</i>, indicating its intention to propose such regulations and issuing certain interim rules on which taxpayers may rely. Under the interim rules, liquidating distributions made by special purpose acquisition companies are exempt from the excise tax. In addition, any redemptions that occur in the same taxable year as a liquidation is completed will also be exempt from such tax. Any redemption or other repurchase that occurs after December 31, 2022, in connection with the Business Combination, extension vote or otherwise (such as in connection with the Third Extension), may be subject to the excise tax depending on a number of factors. Because the excise tax would be payable by the Company and not by the redeeming stockholders, the mechanics of any required payment of the excise tax have not yet been determined. Based on the IR Act and the guidance currently available, the Company does not expect the excise tax to apply to redemptions occurring in the same taxable year as the consummation of the XBP Europe Business Combination, because the fair market value of the common stock to be issued in connection with the consummation of the XBP Europe Business Combination is expected to be larger than the aggregate fair market value of the redeemed shares of the Company’s common stock occurring during 2023. However, if the excise tax is due, it would be payable by the Company and not by the redeeming holder. The obligation of the Company to pay any excise tax could cause a reduction in the cash available on hand to complete the Business Combination, in the Company’s ability to complete the Business Combination, or a reduction in cash available to the Company after consummation of the XBP Europe Business Combination. At this time, it has been determined that none of the IR Act tax provisions have an impact to the Company’s fiscal 2023 tax provision. Management will continue to monitor any updates to the Company’s business along with guidance issued with respect to the IR Act to determine any impact on the Company’s unaudited condensed consolidated financial statements.</p>
CY2023Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts	4900000	usd
CY2023Q3	us-gaap	Other Deferred Costs Net OtherDeferredCostsNet	400000	usd
	cffe	Percentage Of Aggregate Fair Market Value Of Asset PercentageOfAggregateFairMarketValueOfAsset	0.80	pure
	cffe	Redeem Public Share Percentage RedeemPublicSharePercentage	1	pure
CY2022Q3	us-gaap	Loans Payable LoansPayable	976832	usd
CY2022Q3	us-gaap	Investment Company Issuance Of Shares Per Share InvestmentCompanyIssuanceOfSharesPerShare	0.33
	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	1523509	shares
	cffe	Trust Account TrustAccount	16290945	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	65000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41200	usd
CY2023Q3	cffe	Working Capital WorkingCapital	11566000	usd
CY2022Q4	cffe	Working Capital WorkingCapital	9209000	usd
	cffe	Sponsor Exchange SponsorExchange	25000	usd
CY2022Q2	cffe	Working Capital Loan WorkingCapitalLoan	1000000	usd
CY2022Q4	cffe	Working Capital Loan WorkingCapitalLoan	750000	usd
CY2023Q1	cffe	Third Extension Loan ThirdExtensionLoan	344781	usd
CY2023Q1	cffe	Working Capital Loan WorkingCapitalLoan	500000	usd
CY2023Q3	cffe	Working Capital Loan WorkingCapitalLoan	300000	usd
CY2023Q3	us-gaap	Loans Payable LoansPayable	9906000	usd
CY2022Q4	us-gaap	Loans Payable LoansPayable	8500000	usd
	us-gaap	Other Expenses OtherExpenses	100000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these unaudited condensed consolidated financial statements is the determination of the fair value of the warrant liability, FPS liability and sponsor loans liability. Such estimates may be subject to change as more current information becomes available and accordingly, the actual results could differ significantly from those estimates.</p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentration of Credit Risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which, at times, may exceed the Federal Deposit Insurance Corporation maximum coverage limit of $250,000, and cash equivalents held in the Trust Account. Any loss incurred or lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations and cash flows. For the three and nine months ended September 30, 2023 and 2022, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</p>
CY2023Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	210000	usd
	us-gaap	Interest Expense InterestExpense	459000	usd
	cffe	Public Shares PublicShares	669661	shares
CY2023Q3	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	41000	usd
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	67000	usd
CY2023Q3	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	-0.002	pure
	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	-0.003	pure
CY2022Q3	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	98000	usd
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	139000	usd
CY2022Q3	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	-0.138	pure
	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.037	pure
CY2021Q1	cffe	Issued And Outstanding Shares Percentage IssuedAndOutstandingSharesPercentage	0.20	pure
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	29000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	29000	usd
	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	On March 11, 2021, the Company effected a 1.1-for-1 stock split.
CY2021Q1	cffe	Initial Shareholders Holding Percentage InitialShareholdersHoldingPercentage	0.20	pure
	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	733400	shares
CY2023Q3	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	30000	usd
CY2022Q3	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	30000	usd
	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	90000	usd
	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	90000	usd
CY2022Q2	cffe	Working Capital Loan WorkingCapitalLoan	1000000	usd
CY2022Q4	cffe	Working Capital Loan WorkingCapitalLoan	750000	usd
CY2023Q1	cffe	Working Capital Loan WorkingCapitalLoan	500000	usd
CY2023Q3	cffe	Working Capital Loan WorkingCapitalLoan	300000	usd
CY2022Q3	us-gaap	Proceeds From Loans ProceedsFromLoans	976832	usd
CY2023Q1	cffe	Third Extension Loan ThirdExtensionLoan	344781	usd
CY2023Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	9906000	usd
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5540000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	540000	shares
	cffe	Aggregate Converted Basis Percentage AggregateConvertedBasisPercentage	0.20	pure
	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	the Company effected a 1.1-for-1 stock split.
CY2023Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
	us-gaap	Class Of Warrant Or Right Reason For Issuing To Nonemployees ClassOfWarrantOrRightReasonForIssuingToNonemployees	●in whole and not in part; ● at a price of $0.01 per warrant; ● at any time during the exercise period; ● upon a minimum of 30 days’ prior written notice of redemption; ● if, and only if, the last reported sale price of the Company’s common stock equals or exceeds $18.00 per share for any 20-trading days within a 30-trading day period ending on the third business day prior to the date on which the Company sends the notice of redemption to the warrant holders; and ● if, and only if, there is a current registration statement in effect with respect to the shares of common stock underlying such warrants.
CY2023Q3	cffe	Fps Commitment FPSCommitment	10000000	usd
CY2023Q3	us-gaap	Commitments Fair Value Disclosure CommitmentsFairValueDisclosure	10000000	usd
	cffe	Business Combination BusinessCombination	1	pure
CY2022	cffe	Business Combination BusinessCombination	0.80	pure
CY2022Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent		usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023Q3	us-gaap	Other Income OtherIncome		usd
CY2023Q1	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		usd
	us-gaap	Share Based Compensation ShareBasedCompensation		usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities		usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities		usd
	cffe	Proceeds From Trust Account To Pay Income Taxes ProceedsFromTrustAccountToPayIncomeTaxes		usd
	cffe	Proceeds From Trust Account Torepayoverdraftfacility ProceedsFromTrustAccountTorepayoverdraftfacility		usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments		usd
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments		usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt		usd
	cffe	Maturity Of Availableforsale Debt Securities Held In The Trust Account MaturityOfAvailableforsaleDebtSecuritiesHeldInTheTrustAccount		usd
	us-gaap	Proceeds From Repayments Of Bank Overdrafts ProceedsFromRepaymentsOfBankOverdrafts		usd
	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt		usd
	cffe	Prepaid Expenses Paid With Payables To Related Party PrepaidExpensesPaidWithPayablesToRelatedParty		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001839530

Files In Submission

Name	View Source	Status
cffe-20230930_cal.xml	Edgar Link	unprocessable
0001213900-23-086215-index-headers.html	Edgar Link	pending
0001213900-23-086215-index.html	Edgar Link	pending
0001213900-23-086215.txt	Edgar Link	pending
0001213900-23-086215-xbrl.zip	Edgar Link	pending
cffe-20230930.xsd	Edgar Link	pending
f10q0923ex31-1_cfacq8.htm	Edgar Link	pending
f10q0923ex31-2_cfacq8.htm	Edgar Link	pending
f10q0923ex32-1_cfacq8.htm	Edgar Link	pending
f10q0923ex32-2_cfacq8.htm	Edgar Link	pending
f10q0923_cfacq8.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
cffe-20230930_def.xml	Edgar Link	unprocessable
cffe-20230930_lab.xml	Edgar Link	unprocessable
cffe-20230930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
f10q0923_cfacq8_htm.xml	Edgar Link	completed
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$XBP
XBP Europe Holdings Inc Stock $xbp

2023 Q3 Form 10-Q Financial Statement

#000121390023086215 Filed on November 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XBP XBP Europe Holdings Inc Stock $xbp

2023 Q3 Form 10-Q Financial Statement

#000121390023086215 Filed on November 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XBP
XBP Europe Holdings Inc Stock $xbp